Global Brain has invested in GC Therapeutics, Inc. to drive next-generation iPSC cell therapies

Global Brain has invested in GC Therapeutics, Inc. (GCTx), a groundbreaking biotech company advancing next-generation cell therapies using its proprietary TFome™ technology, through its FUKOKU -THE MUTUAL for Next 100 Fund L.P. (TMN100).

Co-founded by renowned geneticist George Church, GCTx is redefining the development of off-the-shelf cell therapies with applications across a wide array of therapeutic areas, including gastrointestinal, neurological, and immunological diseases. With a successful $65M Series A financing, GCTx is poised to revolutionize cell therapy by making these therapies more scalable and accessible to patients worldwide.

GCTx’s TFome™ platform is a leap forward in enabling cell therapies that overcome the limitations of current approaches, which often rely on complex, patient-specific manufacturing processes. The company’s cutting-edge approach unlocks the potential of iPSC-based therapies, which can significantly reduce the time and cost associated with cell reprogramming.

This investment underscores Global Brain's commitment to advancing cutting-edge biotechnology and improving patient outcomes globally. Global Brain is excited to be part of their journey to unlock new treatments that can address critical unmet medical needs.